Due to its limited expression in healthy tissues, MSLN has grown into a therapeutic target for different types of cancers and therapeutic strategies, such as vaccines [60], immunotoxins [61,62,63,64], monoclonal antibodies [65,66], antibody-drug conjugates [67,68] or CAR-T cells [69]. The gene discussed is MSLN; the disease is cancer.